InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.33
(
0.37%
)
Bitcoin
63,203.53
(
0.07%
)

Replies to post #17994 on Momenta Pharmaceuticals, Inc. (MNTA)

Replies to #17994 on Momenta Pharmaceuticals, Inc. (MNTA)

jbog

12/06/17 4:21 PM

#17995 RE: indigokid #17994

D) This is Momenta.

DewDiligence

12/06/17 4:41 PM

#17996 RE: indigokid #17994

My guess is: b). If so, MNTA’s justification could be that MYL’s approval for 40mg Copaxone renders 40mg Glatopa less consequential to MNTA’s business prospects than what is needed to trigger an 8-K.